Literature DB >> 24457276

Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study.

Atsushi Hirohata1, Keizo Yamamoto, Eiki Hirose, Yuhei Kobayashi, Hiroya Takafuji, Fumihiko Sano, Kensuke Matsumoto, Minako Ohara, Ryo Yoshioka, Hiroyuki Takinami, Tohru Ohe.   

Abstract

AIMS: Nicorandil, an ATP sensitive potassium channel opener, may reduce the incidence of microvascular dysfunction after percutaneous coronary intervention (PCI) by dilating coronary resistance vessels. The aim of the study was evaluation of the impact of the administration of intravenous nicorandil on measuring the index of microcirculatory resistance (IMR) in PCI to patients with stable angina pectoris (SAP). METHODS AND
RESULTS: Intravascular ultrasound (IVUS), fractional flow reserve (FFR), IMR and blood examination (CK-MB), cardiac troponin I (cTnI) immediately post-PCI (and 24 hours later) were performed in 62 consecutive patients with SAP undergoing PCI. FFR and IMR were measured simultaneously with a single coronary pressure wire. IMR was defined as Pd/coronary flow (or Pd* mean transit time) at peak hyperaemia. Patients were randomised to the control (n=29), or nicorandil group (n=33). In the nicorandil group, nicorandil was intravenously administered as a 6 mg bolus injection just before PCI and as a constant infusion at 6 mg/hour for 24 hours thereafter. All volumetric IVUS parameters and FFR were similar between the two groups both pre- and post-PCI. However, IMR immediately post-PCI and cTnI 24 hours post-PCI were significantly higher in the control group compared to the nicorandil group (IMR: 25.4±12.1 vs. 17.9±9.1 units, and cTnI: 0.21±0.13 vs. 0.12±0.08 ng/mL, for control vs. nicorandil). The incidence for cTnI elevation more than fivefold the normal range (>0.20 ng/mL) was significantly larger in the control group than in the nicorandil group (41% vs. 12%, p<0.01). Additionally, the control group showed a closer correlation between plaque volume reduction during stenting as assessed by volumetric IVUS, and cTnI elevation than the nicorandil group (r=0.55 vs. 0.42, p<0.001 for control vs. nicorandil).
CONCLUSIONS: In patients undergoing successful coronary stenting for stable angina, administration of nicorandil is associated with reduced microvascular dysfunction induced by PCI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24457276     DOI: 10.4244/EIJV9I9A178

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  11 in total

1.  Predictors of recurrent angina in patients with no need for secondary revascularization.

Authors:  Tian Xu; Ya Li; Li-Ding Zhao; Guo-Sheng Fu; Wen-Bin Zhang
Journal:  World J Emerg Med       Date:  2021

2.  The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI.

Authors:  Jelena Kostic; Ana Djordjevic-Dikic; Milan Dobric; Dejan Milasinovic; Milan Nedeljkovic; Sinisa Stojkovic; Jelena Stepanovic; Milorad Tesic; Zoran Trifunovic; Danijela Zamaklar-Tifunovic; Mina Radosavljevic-Radovanovic; Miodrag Ostojic; Branko Beleslin
Journal:  Cardiovasc Ultrasound       Date:  2015-05-27       Impact factor: 2.062

3.  Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC).

Authors:  Norifumi Kawakita; Kentaro Ejiri; Toru Miyoshi; Kunihisa Kohno; Makoto Nakahama; Masayuki Doi; Mitsuru Munemasa; Masaaki Murakami; Kazufumi Nakamura; Hiroshi Ito
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

Review 4.  Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials.

Authors:  Houyong Zhu; Xiaoqun Xu; Xiaojiang Fang; Jianwu Zheng; Tielong Chen; Jinyu Huang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 5.  The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region.

Authors:  Kevin Cheng; Khaldoon Alhumood; Fayez El Shaer; Ranil De Silva
Journal:  Adv Ther       Date:  2020-12-22       Impact factor: 3.845

Review 6.  Impact of Targeted Therapies for Coronary Microvascular Dysfunction as Assessed by the Index of Microcirculatory Resistance.

Authors:  James Xu; Sidney Lo; Craig P Juergens; Dominic Y Leung
Journal:  J Cardiovasc Transl Res       Date:  2020-07-24       Impact factor: 4.132

7.  Effects of nicorandil on PI3K/Akt signaling pathway and its anti-apoptotic mechanisms in coronary microembolization in rats.

Authors:  Qiang Su; Lang Li; Jinmin Zhao; Yuhan Sun; Huafeng Yang
Journal:  Oncotarget       Date:  2017-08-05

8.  Effect of nicorandil on QT dispersion in patients with stable angina pectoris undergoing elective angioplasty: A triple-blind, randomized, placebo-controlled study.

Authors:  Homa Fal Suleimani; Ali Eshraghi; Mehdi Hasanzadeh Daloee; Sara Hoseini; Nima Nakhaee
Journal:  Electron Physician       Date:  2017-08-25

9.  The Efficacy and Safety of Nicorandil for Periprocedural Myocardial Injury in Patients Undergoing PCI: A Meta-Analysis.

Authors:  Yuanxi Lu; Wenbiao Hu; Qinghua Song; Qiwu Wang
Journal:  J Interv Cardiol       Date:  2020-11-06       Impact factor: 2.279

10.  Effects of Oral Drugs on Coronary Microvascular Function in Patients Without Significant Stenosis of Epicardial Coronary Arteries: A Systematic Review and Meta-Analysis of Coronary Flow Reserve.

Authors:  Jingwen Yong; Jinfan Tian; Xueyao Yang; Haoran Xing; Yi He; Xiantao Song
Journal:  Front Cardiovasc Med       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.